Prelude Therapeutics IncorporatedPRLDNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank57
3Y CAGR-2.1%
5Y CAGR+14.5%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
-2.1%/yr
vs +69.5%/yr prior
5Y CAGR
+14.5%/yr
Recent deceleration
Acceleration
-71.6pp
Decelerating
Percentile
P57
Within normal range
vs 5Y Ago
2x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $115.86M | -21.0% |
| 2024 | $146.71M | +10.9% |
| 2023 | $132.28M | +7.1% |
| 2022 | $123.54M | +8.6% |
| 2021 | $113.73M | +93.5% |
| 2020 | $58.76M | +109.1% |
| 2019 | $28.11M | +87.7% |
| 2018 | $14.97M | - |